INTRODUCTION
Oligohydramnios is a condition in which the amniotic fluid is decreased. It was quantified as an amniotic fluid index (AFI) less than 5 cm. 1 However, now a more commonly used definition of oligohydramnios is amniotic fluid index less than the 5th percentile for the gestational age. 2 Oligohydramnios is associated with an adverse perinatal and maternal outcome. Ultrasound guided amnioinfusion is an option for treatment commonly being employed nowadays. Since it is an invasive procedure there is an inherent risk of fetal loss. Another modality employed since a long period of time is maternal hydration though results have been varied and there is no standard treatment protocol for the same. A recently propagated alternative for the treatment of oligohydramnios is the administration of L-arginine which has been found to be effective in cases of intrauterine growth restriction and Pregnancy Induced Hypertension. 3 However there is no literature as of yet studying the effect of L-arginine on amniotic fluid index.
This study was conducted to see the effect of L-arginine administration on AFI in patients with oligohydramnios.
METHODS
The study was a prospective study conducted Exclusion Criteria: Patient not giving consent for the study, diagnosed major congenital anomalies, history of having received treatment for oligohydramnios.
Methods:
Women who fulfilled the inclusion criteria were prescribed sachets of L-arginine containing 3g of the active ingredient for periods varying between 1 to 4 weeks. Repeat scan was done on follow up and the AFI noted. Change in AFI was noted.
RESULTS
The mean age of women in the study was 24.15±3.38 years. The mean gestational age at diagnosis of oligohydramnios was 31.1±2 weeks (Table 1) . Table 2 ). The average change in AFI was 2.03±0.39 cm (Table 3) . 
DISCUSSION
With the easier availability of ultrasonography nowadays more cases of oligohydramnios are being identified. This helps us to be more cautious and anticipate problems especially during labour. However the need for an effective, economical, easily available treatment modality remains unmet. Maternal dehydration has been always believed to cause oligohydramnios though it cannot be coined as the cause in every case. Recently, serial ultrasound guided amnioinfusions have been tried but with varying success rates. Moreover it carries the inherent danger of fetal loss as it is an invasive procedure. L-arginine is a versatile amino acid with a wide range of biological functions. It serves as a precursor not only to proteins but also nitric oxide which has been identified as endothelium-derived relaxing factor. 4 L-arginine increases uteroplacental blood flow through nitric oxide mediated dilatation of vessels thereby increasing the supply of nutrients to the fetus aiding its growth. In a study by Ropacka et al, L-arginine was found to be effective in cases of Intrauterine growth restriction. 3 Similarly in another study in growth restricted and pre-eclamptic patients by Dera et al, use of L-arginine was associated with lower rate of operative deliveries and higher Apgar scores at both 1 and 5 minutes. 5 In our study the mean age of women was 24.15±3.38 years with a range from 19 years to 35 years. The average gestational age of the women included in the study was 31.1±2 weeks.
In our study the mean duration of treatment was a 23.99±3.51 days which was lesser than in a similar study by Ropacka et al in which duration of therapy in study group was 34.1±13.8 days.
3 This could be due to patients being less compliant with the treatment in our country.
The mean change in AFI in women in our study was 2.03cm±0.39cm. This is a positive effect and it suggests that L-arginine could be useful in cases far from term with oligohydramnios.
In our country where facilities for treatment options like amnioinfusion are not easily available, L-arginine could be used as an effective method of treatment. It has the added advantage of being non-invasive and not requiring hospitalization.
CONCLUSIONS
The present study points towards the effectiveness of Larginine in increasing amniotic fluid index in cases of oligohydramnios. However extensive long-term studies are required to demonstrate not only its efficacy but also its effect on maternal and perinatal outcome which would help in establishing its role as a potent treatment option for oligohydramnios.
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